Mesothelin is shed from tumor cells [3]

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 9, 2006, Pages 1751-

  Ho, Mitchell ^a   Onda, Masanori ^a   Wang, Qing Cheng ^a   Hassan, Raffit ^a   Pastan, Ira ^a   Lively, Mark O ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESOTHELIN; SOLUBLE MESOTHELIN PROTEIN; UNCLASSIFIED DRUG;

BLOOD SAMPLING; ENZYME LINKED IMMUNOSORBENT ASSAY; GLYCOSYLATION; HUMAN; ION TRAP MASS SPECTROMETRY; LETTER; LIQUID CHROMATOGRAPHY; MEDICAL LITERATURE; OVARY CANCER; PRIORITY JOURNAL; TUMOR CELL;

AMINO ACID SEQUENCE; FEMALE; HUMANS; MEMBRANE GLYCOPROTEINS; MOLECULAR SEQUENCE DATA; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33749355981     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-0479     Document Type: Letter

References (5)

1. Hellstrom I, Raycraft J, Kanan S, et al. Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev 2006;15:1014-20.
2. Kojima T, Oh-eda M, Hattori K, et al. Molecular cloning and expression of megakaryocyte potentiating factor cDNA. J Biol Chem 1995;270:21984-90.
3. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 2004;10:3937-42.
4. Scholler N, Fu N, Yang Y, et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci U S A 1999;96:11531-6.
5. Censullo P, Davitz MA. How GPI-anchored proteins turnover: or where do they go after arrival at the plasma membrane. Semin Immunol 1994;6:81-8.